RESULTS: A best-fitting prediction model with seven significant factors was developed. The C-index and two 
INTRODUCTION AND OBJECTIVES:
Upper tract urothelial carcinoma with variant histology (UTUC-VH) has been understudied and its prognostic implication is unknown. We evaluated perioperative and oncologic outcome of patients with UTUC-VH and compared them to pure urothelial carcinoma (PUC) following radical nephroureterectomy (RNU), with the majority of patients undergoing lymph node dissection (LND).
METHODS: Using our IRB approved, prospectively maintained UTUC database, we identified all patients undergoing RNU with intent to cure. Tumors were divided into PUC or VH based on pathologic evaluation at resection. Using Fisher's Exact Test, we compared PUC and VH with primary outcomes of recurrence free survival (RFS) and overall survival (OS). We also examined perioperative outcomes, including 90-day complication and readmission rates.
RESULTS: Of 160 patients undergoing RNU from 2009-2018, 139 patients had PUC (87%), and 21 had VH (13%). The most common histologic variant was squamous (81%), followed by sarcomatoid (14%) and small cell/neuroendocrine (5% 
It is not fully known whether the location of a urothelial carcinoma in the urinary tract can result in a different clinical outcome. As tumor stage is thought to be the most important prognostic indicator for survival, we compared the prognostic differences in tumor location of urothelial carcinoma (bladder urothelial carcinoma, BUC vs renal pelvis urothelial carcinoma, PUC vs ureter urothelial carcinoma, UUC). METHODS: We identified 449 patients who underwent total cystectomy for BUC or radical nephroureterectomy for PUC and UUC at our 4 institutions. Among them, 125 patients had pT2 tumors (BUC in 69, PUC in 20, UUC in 36) and 324 patients had pT3/4 tumors (BUC in 139, PUC in 113, UUC in 72. We evaluated the oncological outcome of tumor recurrence and cancer death in these three groups.
RESULTS: In patients with a pT2 tumor, 33.3% received neoadjuvant and/or adjuvant chemotherapy for BUC, which was significantly higher than 5.0% for PUC, and 14.7% for UUC. A history of smoking was present in 66.2% of BUC patients, 50.0% of PUC patients, and 71.9% of UUC patients, with no statistical significance (NS). Of the patients with a pT2 tumor, the 5-year recurrence free survival (RFS) for BUC was 64.5%, which was not significantly different to that for PUC (69.4%) and UUC (82.7%) and the 5-year cancer specific survival (CSS) for BUC was 74.9%, which was not significantly different to that for PUC (80.0%) and UUC (83.7%). In patients with a pT3/4 tumor, 44.9% received neoadjuvant and/or adjuvant chemotherapy for BUC, which was significantly higher than 32.4% for PUC, and 28.1% for UUC. A history of smoking was present in 64.2% of BUC patients, 59.1% of PUC patients, and 50.0% of UUC (NS). Of the patients with a pT3/4 tumor, the 5-year RFS for BUC was 32.4%, which was significantly lower than that for PUC (58.2%, p[0.001) 
